Clinical Trial Update: Evaluation of the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating [123I]NAV5001 as an imaging agent for diagnosing Parkinsonian syndromes has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease
• Parkinsonian Syndrome

Drugs mentioned

• [123I]NAV5001

Snippet

Sponsor: Navidea Biopharmaceuticals | Conditions: Parkinson's Syndrome | Phase 3 | Status: TERMINATED